Fulvestrant

Grey

Brand Name(s):Faslodex

Indication:Hormone receptor-positive advanced breast cancer failed on a non-steroidal aromatase inhibitor (NSAI).

Rationale:1

Considered:May-07

Review Date:Feb-23

Comments:
NICE TA503
Fulvestrant is not recommended, within its marketing authorisation, for treating
locally advanced or metastatic oestrogen-receptor positive breast cancer in
postmenopausal women who have not had endocrine therapy before
Jan 2018
…………………………
Fulvestrant for the treatment of locally advanced or
metastatic breast cancer
Guidance
Fulvestrant is not recommended, within its licensed indication, as an
alternative to aromatase inhibitors for the treatment of oestrogen-receptorpositive,
locally advanced or metastatic breast cancer in postmenopausal
women whose cancer has relapsed on or after adjuvant anti-oestrogen
therapy, or who have disease progression on anti-oestrogen therapy.
Post-menopausal women currently receiving fulvestrant within its licensed
indication as an alternative to aromatase inhibitors for the treatment of
oestrogen-receptor-positive, locally advanced or metastatic breast cancer
whose cancer has relapsed on or after adjuvant anti-oestrogen therapy, or who
have disease progression on anti-oestrogen therapy, should have the option to
continue treatment until they and their clinicians consider it appropriate to stop.

NICE technology appraisal guidance 239 December 2011